Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Last trade$25.86
Day change+$0.315 (+1.23%)
Day range$24.69 – $25.94
Volume2,078,974
Market cap$13.21B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.21B
Price / earnings
—
Price / book
2.03×
Price / sales
1.14×
EV / sales
1.71×
EV / EBITDA
17.21×
Profitability
Earnings per share
-$1.29
Return on assets
-3.43%
Return on equity
-10.24%
Dividend yield
0.77%
Liquidity and leverage
Debt / equity
1.32×
Current ratio
1.79×
Quick ratio
1.19×
Cash ratio
0.52×
Cash flow
Price / cash flow
8.06×
Price / free cash flow
11.62×
Free cash flow
$1.14B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BAX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.98B
$2.96B
$2.7B
$2.97B
$2.84B
$2.81B
$2.63B
$2.75B
Cost of revenue
$1.98B
$1.93B
$1.81B
$2.4B
$1.89B
$1.82B
$1.76B
$1.79B
Gross profit
$994M
$1.03B
$891M
$577M
$950M
$991M
$861M
$959M
Selling, general and administrative
$730M
$735M
$728M
$761M
$708M
$718M
$703M
$761M
Research and development
$125M
$129M
$139M
$126M
$118M
$134M
$140M
$211M
Total operating expenses
$769M
$815M
$825M
$1.37B
$778M
$800M
$803M
$1.4B
Operating income
$225M
$217M
$66M
-$795M
$172M
$191M
$58M
-$438M
Interest expense
-$61M
-$64M
$0
$0
-$58M
-$58M
$0
$0
Income before taxes
$417M
$158M
-$6M
-$756M
$121M
$133M
-$3M
-$521M
Income taxes
$119M
$23M
$11M
$279M
$172M
$11M
-$67M
-$33M
Net income
$294M
$126M
-$15M
-$1.07B
-$46M
$91M
$126M
-$209M
Net income attributable to common shareholders
$294M
$126M
-$15M
-$1.07B
-$46M
$91M
$126M
-$189M
EBITDA
$464M
$456M
$303M
-$70M
$409M
$448M
$305M
$232M
Basic earnings per share
$0.57
$0.24
-$0.03
-$2.09
-$0.09
$0.18
$0.25
-$0.37
Diluted earnings per share
$0.57
$0.24
-$0.03
-$2.10
-$0.09
$0.18
$0.25
-$0.37
Recent news
Company coverage with links to the original publishers.
The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.
Baxter International (BAX) reported Q3 adjusted EPS of 58 cents, beating estimates by 13.7%, with revenues up 5% to $2.98 billion. The company raised its 2026 sales growth outlook to 4-5% and adjusted EPS guidance to $2.05-$2.15, driven by strong performance in Medical Products & Therapies and Healthcare Systems & Technologies segments. However, adjusted operating margins contracted 40 basis points due to cost pressures.
Baxter International (BAX) is expected to report Q3 2026 results on October 29 with revenues projected to grow 2.4% to $2.90B, but EPS is forecast to decline 26.1% to 51 cents. While Advanced Surgery products and IV solutions should drive growth, the company faces headwinds from infusion pump issues, elevated manufacturing costs, and $40M in tariff-related expenses. The Zacks model does not predict an earnings beat.
Zacks highlights two Medical-Products stocks with strong value characteristics: Baxter International (BAX) and Zimmer Biomet (ZBH), both holding Zacks Rank #2 (Buy) ratings and Value grade A. Both stocks trade at attractive valuations compared to industry averages across multiple metrics including P/E, PEG, P/B, and P/S ratios, suggesting they are currently undervalued with strong earnings outlooks.
Baxter International (BAX) has significantly outperformed the medical sector year-to-date, returning 26.7% compared to the sector's -0.2% average loss. The stock holds a Zacks Rank #2 (Buy) with improving analyst sentiment, as consensus earnings estimates have increased 6.5% in the past quarter. BAX is outperforming its Medical-Products industry peers, which have declined 22.4% on average.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.01 per share
Declared
Oct 28, 2026
Ex-dividend
Nov 27, 2026
Pay date
Jan 4, 2027
Ex-dividend
Amount / share
Pay date
Type
Aug 28, 2026
$0.01
Oct 1, 2026
recurring
May 29, 2026
$0.01
Jul 1, 2026
recurring
Feb 27, 2026
$0.01
Apr 1, 2026
recurring
Nov 28, 2025
$0.01
Jan 2, 2026
recurring
Aug 29, 2025
$0.17
Oct 1, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.